FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Quinoline topics
Isoquinolin
Praziquantel
Carbon Atoms
Crystallin
Quinoline Derivatives
Pharmaceutically Acceptable Salt
Alkyl Group
Cycloalkyl
Pharmaceutically Acceptable Salts
Immunodeficiency
Retrovirus
Viral Infection
Human Immunodeficiency Virus
Angiogenesis
Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Quinoline patents



      
           
This page is updated frequently with new Quinoline-related patent applications. Subscribe to the Quinoline RSS feed to automatically get the update: related Quinoline RSS feeds. RSS updates for this page: Quinoline RSS RSS


Date/App# patent app List of recent Quinoline-related patents
09/04/14
20140249312
 [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer patent thumbnail[1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. Hepatocellular carcionoma (hcc).
09/04/14
20140249201
 Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds patent thumbnailBeta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents.
09/04/14
20140249174
 Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline patent thumbnailAryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
Wherein the variables r1, r2, r3, r4, and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (hsd) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia..
09/04/14
20140249144
 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient patent thumbnailProphylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient
Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of epo and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and epo production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein r1, r2, r2′, r3 and r3′ independently represent a hydrogen atom, a c1-6 alkyl group, or the like; r4, r5, r6, r7, r8, r9 and r10 independently represent a hydrogen atom, a halogen atom, a c1-6 alkyl group, or the like; a represents n—r11, a sulfur atom, or an oxygen atom; r11 represents a hydrogen atom, a c1-6 alkyl group, or the like; b represents a c6-14 aryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt..
08/28/14
20140243524
 Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin patent thumbnailAryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
With r1, r2, r3, r4, r5, r6, r7, r8, and r14 defined herein.. .
08/28/14
20140243396
 Method of treating mucoepidermoid carcinoma patent thumbnailMethod of treating mucoepidermoid carcinoma
Imidazoquinolines, as set forth in formula (i), are useful for inhibiting growth or proliferation of mucoepidermoid carcinoma cells. The therapeutic and prophylactic treatments provided by this invention are practiced by administering to a patient in need thereof an amount of a compound of formula (i) that is effective to inhibit growth or proliferation of the mucoepidermoid carcinoma cells..
08/28/14
20140243311
 Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these patent thumbnailNovel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these
The present invention provides compounds represented by the general formula (i): or pharmaceutical acceptable salts thereof, wherein r1 is cyano or the like; r2 and r3 are hydrogen or the like; r4 is c1-6 alkyl or the like; r5 is c1-6 alkyl, halo-c1-6 alkyl, cycloalkyl, cycloalkyl-c1-6 alkyl, aralkyl or the like; r6 and r7 are each hydrogen, c1-6 alkyl, halo-c1-6 alkyl, cycloalkyl, c1-6 alkoxy-c1-6 alkyl, r12r13n—c1-6 alkyl or the like, which exhibit potent dopamine d2 receptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof..
08/28/14
20140242172
 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide patent thumbnailSolid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
The present invention relates to solid state forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1), pharmaceutical compositions thereof and methods therewith.. .
08/28/14
20140242121
 Novel imidazole quinoline-based immune system modulators patent thumbnailNovel imidazole quinoline-based immune system modulators
The present invention relates to a compound of formula i: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.. .
08/21/14
20140235862
 Method for producing 4, 4-difluoro-3,4-dihydroisoquinoline derivatives patent thumbnailMethod for producing 4, 4-difluoro-3,4-dihydroisoquinoline derivatives
Is reacted with hydrogen fluoride.. .
08/21/14
20140235644
Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
Wherein the wedged bonds, r1, r2, r3, r4, r5, r5a, r6, r7, r8, r9, r10, r11, r12, r13, r14, x and y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula i, by reacting formula i with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula i, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier..
08/21/14
20140235593
Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
In one aspect, the invention relates to novel substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating and/or preventing malaria. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
08/14/14
20140228576
Method for producing 3,4-dihydroisoquinoline derivatives and production intermediates of same
Provided are an efficient method for producing 3,4-dihydroisoquinoline derivatives and useful production intermediates thereof. Provided is a method for producing 3,4-dihydroisoquinoline derivatives represented by general formula (1), comprising converting a compound represented by general formula (3) in the presence of acid after reacting with an aniline derivative, or converting a compound represented by general formula (3) by reacting with an aniline derivative in the presence of an acid..
08/14/14
20140228575
Process for the preparation of solifenacin and salts thereof
The invention provides a new process for the preparation of solifenacin or a pharmaceutically acceptable acid addition salt thereof, comprising reacting (r)-quinuclidin-3-yl phenethylcarbamate with benzaldehyde in the presence of an acid to obtain a diasteroisomeric mixture (s,r)—((r)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate of formula (iv) which can be resolved and the solifenacin or a pharmaceutically acceptable acid addition salt thereof recovered. The invention also provides the new key intermediate (r)-quinuclidin-3-yl phenethylcarbamate involved in the process.
08/14/14
20140228572
Method for producing optically active tetrahydroquinolines
In the presence of a hydrogen donor compound and an iridium (iii) complex having a chiral prolinamide compound as a ligand to give an optically active 2-substituted-1,2,3,4-tetrahydroquinoline represented by formula [ii]:. .
08/14/14
20140228392
Compositions and methods for treating cancer
The present invention is bis-acridine or bis-quinoline intercalators having a modified bis(4-aminophenyl)ether tether to improve activity, selectivity, solubility and bioavailability of the antitumor compound.. .
08/14/14
20140228371
Quinoline and quinazoline amides as modulators of sodium channels
The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.. .
08/07/14
20140221424
Pharmaceutical compositions for use in the treatment of cystic fibrosis
The present invention relates to the use of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and pharmaceutical compositions thereof for the treatment of cystic fibrosis, in patients, including kits and/or products thereof.. .
08/07/14
20140221364
Tetrahydroquinoline analogues as muscarinic agonists
The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.. .
07/24/14
20140206876
2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists
Provided is a 2-(substituted ethynyl)quinoline derivative having an mglur5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mglur5 receptor-mediated diseases such as alzheimer's disease, senile dementia, parkinson's disease, l-dopa-induced dyskinesia, huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile x syndrome, autism, migraine and gastroesophageal reflux disease (gerd)..
07/24/14
20140206719
Crystal form of quinoline compound and process for its production
The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form a, thereby to obtain a drug substance excellent in stability.. .
07/24/14
20140206713
Benzoquinoline inhibitors of vesicular monoamine transporter 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof.. .
07/24/14
20140206712
Benzoquinoline inhibitors of vesicular monoamine transporter 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof.. .
07/17/14
20140200346
Novel process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline
The present invention provides a new process of synthesis of a polymorph of 7-chloro-4-(piperazin-1-yl)-quinoline of formula i. Said quinoline compound is substantially pure of any impurities.
07/17/14
20140200242
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
The present invention is directed to processes for making and compositions containing quinolines such as formula i or pharmaceutically acceptable salts thereof wherein: x1 is h, br, ci, or x2 is h, br, ci, or n1 is 1-2; and n2 is 1-2.. .
07/17/14
20140200222
N-linked quinolineamide m1 receptor positive allosteric modulators
The present invention is directed to n-linked quinoline amide compounds of general formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
07/10/14
20140194435
Novel substituted indolo 4,3 fg quinolines useful for treating migraine
Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein.
07/10/14
20140194434
Novel substituted indolo 4,3 fg quinolines useful for treating migraine
Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein.
07/03/14
20140187787
Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
The present invention relates to processes for preparing solid state forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide, including compound 1 form a, compound 1 form a-hcl, compound 1 form b, and compound 1 form b-hcl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.. .
07/03/14
20140187785
Process for the preparation of pyrido[2,1-a] isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine
Wherein r2, r3, r4 and prot are as defined in the specification.. .
07/03/14
20140187547
Azaindenoisoquinoline topoisomerase i inhibitors
The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase i, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.. .
07/03/14
20140186965
Methods to dissolve beryllium and its compounds present in samples to facilitate determination of beryllium in these samples
A safer, low-cost practical method of dissolving beryllium or a beryllium compound including beryllium oxide in a sample is disclosed. This method discloses use of acidic solutions under mild heating conditions to dissolve beryllium and its compounds.
07/03/14
20140186280
Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
8-hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective mao-ab inhibitory activities.. .
07/03/14
20140183503
Light-emitting element, light-emitting device, electronic appliance, and lighting device
Disclosed is a light-emitting element having high emission efficiency, capable of driving at low voltage, and showing a long lifetime. The light-emitting element contains a compound between a pair of electrodes, and the compound is configured to give a first peak of m/z around 202 and a second peak of m/z around 227 in a mass spectrum.
07/03/14
20140183413
Quinoline-benzoxazole derived compounds for electronic films and devices
Or a combination thereof (c). For each formula, the r groups are described herein..
06/26/14
20140179923
New ligands of the benzo[h]quinoline class and transition metal complexes containing them and use of said complexes as catalysts
A new class of ligands derived from benzo[h]quinoline are described and these ligands are used to prepare several novel transition metal complexes. The complexes are preferably of the group viii transition metals iron, ruthenium or osmium, with the benzo[h]quinoline ligands acting as tridentate ligands.
06/26/14
20140178316
Skin treatments containing pyrroloquinoline quinone (pqq) esters and methods of preparation and use thereof
The present invention relates to cosmetic or dermatological compositions containing pqq or its esters, methods of treating or promoting skin changes by topical application of these compositions, and methods of synthesis of pqq esters. The pqq ester-containing compositions of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance.
06/26/14
20140175406
Phosphorescent compounds and organic light emitting diode devices using the same
Where x, y, and z are each selected from the group consisting of carbon and nitrogen, and when x, y, and z are all carbon, r is any one selected from the group consisting of carbazole, α-carboline, β-carboline, γ-carboline, fluorine, dibenzothiophene, dibenzofuran, triphenylsilane, tetraphenylsilane, pyridine, quinoline, isoquinoline, pyrimidine, diphenylphosphineoxide, and substituents thereof.. .
06/19/14
20140171462
4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
06/19/14
20140171384
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
A combination of a 4-anilino-3-cyanoquinoline compound (e.g. Hki-272, ski-606, ekb-569) and a capecitabine compound in the treatment of a neoplasm is provided.
06/12/14
20140163068
Pharmaceutical compositions for the treatment of cftr mediated diseases
Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (compound 1) in form i and a solid dispersion comprising substantially amorphous n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide (compound 2), methods of treating, lessening the severity of, or symptomatically treating cftr mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.. .
06/05/14
20140155610
Preparation of pyridonecarboxylic acid antibacterials
1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.. .
06/05/14
20140155396
C-met modulators and method of use
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-met, kdf, c-kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
06/05/14
20140154272
Compound and method for modulating opioid receptor activity
The invention provides a compound of formula (i), wherein r1 is h, c(nh)nh2, an amino acid, or a peptide; x is oh, nh2, nhr2, nr2r3, an amino acid, or a peptide; r2 and r3 are selected from alkyl, alkylenearyl, or alkyleneheteroaryl; each r4 and r5 is independently h or ch3; z is 2-amino-2,3-dihydro-1h-indene-2-carboxylic acid; 2-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid; 6-amino-6,7,8,9-tetrahydro-5h-benzo[7]annulene 6-carboxylic acid; cyclohexylalanine; cyclohexylglycine; homophenylalanine; 1-naphthylalanine; 2-naphthylalanine; 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; or octahydro-1h-indole-2-carboxylic acid; n is 0, 1, 2, 3, or 4; with the proviso that x is not nh2 when r1 is h, r4 is h, r5 is ch3, z is aci, and n is 2; or a pharmaceutically acceptable salt, ester or solvate thereof. A method of treating pain and a method for treating a mu-opioid receptor mediated disorder and/or a delta-opioid receptor mediated disorder also are provided..
05/29/14
20140148478
Heteroquinoline-3-carboxamides as kcnq2/3 modulators
The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.. .
05/22/14
20140142312
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
The present invention relates to crystalline solvate forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1) and methods for their preparation. The present invention further relates to pharmaceutical compositions comprising the crystalline solvate forms, as well as methods of treatment therewith..
05/22/14
20140142138
Pharmaceutical compositions and administrations thereof
The present invention relates to the use of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of cftr mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.. .
05/08/14
20140128609
Pyrroloquinoline quinone disodium salt crystal and method for producing the same
An object of the present invention is to provide a novel pyrroloquinoline quinone disodium crystal having excellent dispersibility in solvents and excellent permeability through skin, and a method for producing the pyrroloquinoline quinone disodium crystal with high efficiency. According to the present invention, provided are a novel pyrroloquinoline quinone disodium crystal which is produced by drying a crystal produced under specified conditions through a drying means such as lyophilization, ambient drying and vacuum drying, and a method for producing the pyrroloquinoline quinone disodium crystal..
05/08/14
20140128367
Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
The invention provides certain cycloalkyl-fused tetrahydroquinolines of the formula (i), and their pharmaceutically acceptable salts and esters, wherein r1, r2, r7, r8a, e, y, z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of crth2 function..
05/08/14
20140127288
Liposome containing pyrroloquinoline quinone and sugar
An object of the present invention is to provide a composition that enables extension of the concentration range in which pyrroloquinoline quinone exerts cell growth-promoting function, and an efficient method of producing the composition. According to the present invention, there is provided a liposome composition comprising liposomes individually containing pyrroloquinoline quinone or a salt thereof and sugar, 50% or more of the liposomes having a particle diameter in the range of from 1 to 10 μm, and a method of producing the composition..
05/01/14
20140116696
Compositions and methods related to mitigating aluminum and ferric precipitates in subterranean formations after acidizing operations
Trivalent-ion chelating agents may be useful in mitigating the formation aluminum and ferric precipitates in subterranean formations during acidizing operations. An acidizing operation may include introducing an acidizing fluid into a wellbore penetrating a subterranean formation, the acidizing fluid comprising an aqueous fluid, an acid source, and a trivalent-ion chelating agent, e.g., hydroxamates, 6,7-dihydroxyquinoline, 3-hydroxy-4-pyridinones, and any combination thereof.
04/24/14
20140113896
Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
The present invention relates to substituted phenoxypyridine compounds of general formula (i); in which r1, r2 and r3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.. .
04/24/14
20140113877
Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
In which a, x, r1, r2, r3 and r7 have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.. .
04/24/14
20140112988
Pharmaceutical composition and administrations thereof
The present invention relates to pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.. .
04/24/14
20140112946
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoromethyl)-phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-n methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g.
04/24/14
20140112868
Novel tetrahydroisoquinoline compounds for use in the diagnosis and treatment of neurodegenerative diseases
The invention relates to a new class of compounds with high affinity and selectivity towards p-glycoprotein. The invention also relates to the utilization of such compounds in the in vivo diagnosis of neurodegenerative diseases and as medicaments for use in the prevention and treatment of neurodegenerative disease involving p-glycoprotein..
04/17/14
20140107153
Therapeutic quinoline and naphthalene derivatives
Therapeutic methods, compositions, and medicaments related thereto are also disclosed.. .
04/17/14
20140107127
Pyrazinoisoquinoline compounds
This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel.
04/17/14
20140103305
5-substituted 2-phenylquinoline complexes materials for light emitting diode
Compounds are provided that comprise a ligand having a 5-substituted 2-phenylquinoline. In particular, the 2-phenylquinoline may be substituted with a bulky alkyl at the 5-position.
04/10/14
20140100234
Quinoline derivatives as pi3 kinase inhibitors
Invented is a method of inhibiting the activity/function of pi3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives..


Popular terms: [SEARCH]

Quinoline topics: Isoquinolin, Praziquantel, Carbon Atoms, Crystallin, Quinoline Derivatives, Pharmaceutically Acceptable Salt, Alkyl Group, Cycloalkyl, Pharmaceutically Acceptable Salts, Immunodeficiency, Retrovirus, Viral Infection, Human Immunodeficiency Virus, Angiogenesis, Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Quinoline for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Quinoline with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.8052

3385

5 - 0 - 72